Metabolic Factors and Prostate Cancer Risk

Clin Chem. 2019 Jan;65(1):42-44. doi: 10.1373/clinchem.2018.287243. Epub 2018 Nov 20.

Authors

Barbra Dickerman¹, Lorelei Mucci²

Affiliations

¹ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
² Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA. lmucci@hsph.harvard.edu.

PMID: 30459168
DOI: 10.1373/clinchem.2018.287243

No abstract available

MeSH terms

Androgen Antagonists / therapeutic use
Diabetes Mellitus, Type 2 / complications
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / complications
Hypercholesterolemia / drug therapy
Male
Metabolic Syndrome / complications
Obesity / complications
Prognosis
Prostatic Neoplasms / complications
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / metabolism*
Prostatic Neoplasms / pathology
Risk Factors

Substances

Androgen Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors